439 related articles for article (PubMed ID: 18603570)
21. Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases.
Stoica-Mustafa E; Pechianu C; Iorgescu A; Hortopan M; Dima SO; Tomulescu V; Dumitraşcu T; Ungureanu C; Andronesi D; Popescu I; Herlea V
Rom J Morphol Embryol; 2012; 53(2):351-5. PubMed ID: 22732805
[TBL] [Abstract][Full Text] [Related]
22. The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET).
Kanakis G; Kamp K; Tsiveriotis K; Feelders RA; Zormpala A; de Herder WW; Kaltsas G
Clin Endocrinol (Oxf); 2013 Jun; 78(6):950-6. PubMed ID: 22970733
[TBL] [Abstract][Full Text] [Related]
23. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
24. Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours.
Pascher A; Klupp J; Neuhaus P
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):637-48. PubMed ID: 16183532
[TBL] [Abstract][Full Text] [Related]
25. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
26. Results following surgical resection for malignant pancreatic neuroendocrine tumours. A single institutional experience.
Bonney GK; Gomez D; Rahman SH; Verbeke CS; Prasad KR; Toogood GJ; Lodge JP; Menon KV
JOP; 2008 Jan; 9(1):19-25. PubMed ID: 18182738
[TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital.
Rothenstein J; Cleary SP; Pond GR; Dale D; Gallinger S; Moore MJ; Brierley J; Siu LL
Am J Clin Oncol; 2008 Feb; 31(1):64-70. PubMed ID: 18376230
[TBL] [Abstract][Full Text] [Related]
28. [Operative management and long-term survival in patients with neuroendocrine tumors of the pancreas--experience with 144 patients].
Fendrich V; Habbe N; Celik I; Langer P; Zielke A; Bartsch DK; Rothmund M
Dtsch Med Wochenschr; 2007 Feb; 132(5):195-200. PubMed ID: 17252361
[TBL] [Abstract][Full Text] [Related]
29. Small intestinal neuroendocrine tumors: prognostic factors and survival.
Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
[TBL] [Abstract][Full Text] [Related]
30. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic head carcinoma: clinical analysis of 189 cases.
Hua YP; Liang LJ; Peng BG; Li SQ; Huang JF
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):79-84. PubMed ID: 19208521
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
33. [Liver resection for non-colorectal, non-neuroendocrine liver metastases--is hepatic resection justified as part of the oncosurgical treatment?].
Lehner F; Ramackers W; Bektas H; Becker T; Klempnauer J
Zentralbl Chir; 2009 Sep; 134(5):430-6. PubMed ID: 19757343
[TBL] [Abstract][Full Text] [Related]
34. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
Auernhammer CJ; Jauch KW; Hoffmann JN
Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
[TBL] [Abstract][Full Text] [Related]
35. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
Cunningham JL; Grimelius L; Sundin A; Agarwal S; Janson ET
Acta Oncol; 2007; 46(6):747-56. PubMed ID: 17653896
[TBL] [Abstract][Full Text] [Related]
36. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
37. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.
Rorstad O
J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376
[TBL] [Abstract][Full Text] [Related]
38. Metastatic lymph node ratio is an independent prognostic factor in gastric cancer.
Asoglu O; Karanlik H; Parlak M; Kecer M; Muslumanoglu M; Igci A; Ozmen V; Gulluoglu M; Kapran Y
Hepatogastroenterology; 2009; 56(91-92):908-13. PubMed ID: 19621727
[TBL] [Abstract][Full Text] [Related]
39. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
[TBL] [Abstract][Full Text] [Related]
40. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
